Trial Profile
A real-world analysis comparing glucose lowering in type 2 diabetes patients treated with canagliflozin (Invokana) and those with DPP-4 inhibitors
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 17 Mar 2016 New trial record
- 14 Mar 2016 Results from the real-world analysis published in a Janssen media release.